Nuclera, a biotechnology company enabling rapid access to high-quality proteins, and leadXpro, a specialist in structure-based drug discovery, have announced a strategic scientific partnership aimed at accelerating therapeutic discovery targeting complex membrane proteins. The collaboration will combine artificial intelligence, rapid protein synthesis, and structural biology to create a faster, more efficient pathway for developing new medicines.
Membrane proteins are among the most important targets in modern drug discovery, accounting for a significant proportion of approved therapies. They play critical roles in cellular communication, signal transmission, and molecular transport. However, their complex structure and instability outside natural cellular environments make them extremely difficult to express, purify, and analyze—often delaying or preventing drug development programs.
AI-Integrated Platform to Overcome Drug Discovery Bottlenecks
The partnership integrates Nuclera’s eProtein Discovery™ platform, which uses advanced Cell-Free Protein Synthesis technology to rapidly produce and screen membrane proteins, with leadXpro’s AI- and machine learning-driven construct design and structural biology capabilities. This combined approach creates an AI-guided, end-to-end workflow that connects computational design with rapid experimental validation.
Through this workflow, researchers will be able to:
- Rapidly design optimized membrane protein variants using AI models
- Produce and screen multiple protein constructs simultaneously
- Identify the most stable and functional protein structures faster
- Perform detailed structural analysis using high-resolution cryo-electron microscopy (cryo-EM)
- Continuously refine AI models using experimental feedback to improve accuracy
This iterative process significantly improves efficiency and reduces the trial-and-error typically associated with membrane protein research.
Accelerating Therapeutic Development and Reducing Risk
By combining predictive AI with real-world laboratory testing, the collaboration will help scientists gain critical structural and biophysical insights earlier in the drug discovery process. This allows pharmaceutical researchers to make better-informed decisions, prioritize promising drug candidates, and reduce costly late-stage failures.
The partnership also aims to embed AI-driven predictive design directly into Nuclera’s platform, enabling researchers to quickly move from genetic sequence to fully characterized protein targets. This capability will help accelerate the discovery of treatments for complex diseases, including cancer, neurological disorders, cardiovascular conditions, and rare genetic diseases.
In addition, leadXpro’s expertise in membrane protein characterization and structural analysis will ensure that promising protein targets can be stabilized and analyzed efficiently, improving the overall success rate of structure-based drug discovery programs.
Industry Impact and Future Innovation
This collaboration represents a major step toward integrating artificial intelligence with automated laboratory workflows, transforming how difficult protein targets are studied. By reducing development timelines and improving reliability, the partnership is expected to benefit biotechnology and pharmaceutical companies seeking faster, more efficient therapeutic development.
Dr. Michael Chen, CEO and co-founder of Nuclera, said:
“Scientists are under increasing pressure to accelerate complex drug discovery programs. By combining AI-driven construct design with rapid multiplex protein screening, we can enable researchers to generate structural insights much faster and unlock new therapeutic opportunities.”
Dr. Michael Hennig, CEO of leadXpro, added:
“Optimized membrane protein constructs are essential for successful drug discovery. Integrating our AI expertise with Nuclera’s rapid protein synthesis platform allows us to accelerate structural studies and support the development of next-generation therapies.”
Strengthening the Future of AI-Powered Drug Discovery
The partnership also supports the broader trend of using artificial intelligence to improve precision, efficiency, and scalability in drug development. By creating a seamless integration between computational modeling and experimental biology, Nuclera and leadXpro are helping establish a new standard for structure-based drug discovery.
As pharmaceutical companies increasingly focus on complex and previously inaccessible drug targets, this collaboration is expected to play a key role in enabling faster innovation, reducing research risks, and bringing life-saving therapies to patients sooner.